The FDA has granted Orphan Drug designation to riliprubart for the investigational treatment of AMR in solid organ transplantation.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

The FDA has awarded the fast-track designation for the CKD indication based on that result, as well as the promise of an ongoing trial – EMPA-KIDNEY – which is looking at kidney disease ...

Mineralys Therapeutics announced positive topline results from its phase 2 Explore-CKD trial, in which lorundrostat lowered ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

The United States market has remained flat over the past week but has shown a 10.0% increase over the past year, with earnings projected to grow by 15% annually. In this context, identifying ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the ...